Recent Finacing
Recent Raise
IM Therapeutics is a clinical-stage company developing personalized oral HLA-blocking therapies using computational chemistry, bioassays, and rational design to screen compounds; lead IMT-002 targets HLA‑DQ8 for type 1 diabetes.
